All In Biotech

Free tool

FAERS Monitor: Tibsovo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211192 or its brand name (Tibsovo, Ivosidenib). Reports on generic versions are filed under their own applications.

Reports

2,178

Serious

1,366

63% of reports

Hospitalization

713

Death reported

229

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use656
  • fatigue171
  • nausea124
  • diarrhoea123
  • differentiation syndrome100
  • malignant neoplasm progression89
  • disease progression88
  • product use issue88
  • febrile neutropenia87
  • drug ineffective83
  • electrocardiogram qt prolonged78
  • neutropenia76
  • platelet count decreased76
  • death74
  • product dose omission issue74

Reports by year received

View as table
YearReports
20174
201823
2019236
2020431
2021398
202299
2023176
2024175
2025290
2026346

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,981 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
differentiation syndromeSignal1001524.61239.9130,205
electrocardiogram qt prolongedSignal7821.016.91,464
febrile neutropeniaSignal8712.710.3926
malignant neoplasm progressionSignal898.46.9575
off label useSignal6567.26.83,672
disease progressionSignal887.25.9465
platelet count decreasedSignal766.95.5378
neutropeniaSignal765.44.3270
product use issueSignal884.53.7240
product dose omission issueSignal742.41.962
fatigueSignal1712.11.8104
diarrhoea1231.81.548
nausea1241.51.322
death740.80.73
drug ineffective830.60.522

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.